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The Alpha-1D Is the Predominant
Alpha-1-Adrenergic Receptor Subtype
in Human Epicardial Coronary Arteries
Brian C. Jensen, MD,*† Philip M. Swigart, MS,* Marie-Eve Laden, MD,* Teresa DeMarco, MD,†
Charles Hoopes, MD,‡ Paul C. Simpson, MD*†
San Francisco, California
Objectives The goal was to identify alpha-1-adrenergic receptor (AR) subtypes in human coronary arteries.
Background The 1-ARs regulate human coronary blood flow. The 1-ARs exist as 3 molecular subtypes, 1A, 1B, and 1D,
and the 1D subtype mediates coronary vasoconstriction in the mouse. However, the 1A is thought to be the
only subtype in human coronary arteries.
Methods We obtained human epicardial coronary arteries and left ventricular (LV) myocardium from 19 transplant recipi-
ents and 6 unused donors (age 19 to 70 years; 68% male; 32% with coronary artery disease). We cultured coro-
nary rings and human coronary smooth muscle cells. We assayed 1- and -AR subtype messenger ribonucleic
acid (mRNA) by quantitative real-time reverse transcription polymerase chain reaction and subtype proteins by
radioligand binding and extracellular signal-regulated kinase (ERK) activation.
Results The 1D subtype was 85% of total coronary 1-AR mRNA and 75% of total 1-AR protein, and 1D stimulation
activated ERK. In contrast, the 1D was low in LV myocardium. Total coronary 1-AR levels were one-third of
-ARs, which were 99% the 2 subtype.
Conclusions The 1D subtype is predominant and functional in human epicardial coronary arteries, whereas the 1A and
1B are present at very low levels. This distribution is similar to the mouse, where myocardial 1A- and 1B-
ARs mediate beneficial functional responses and coronary 1Ds mediate vasoconstriction. Thus, 1D-selective
antagonists might mediate coronary vasodilation, without the negative cardiac effects of nonselective 1-AR
antagonists in current use. Furthermore, it could be possible to selectively activate beneficial myocardial 1A-
and/or 1B-AR signaling without causing coronary vasoconstriction. (J Am Coll Cardiol 2009;54:1137–45)
© 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.056r
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idrenergic receptors (ARs) play an important role in coronary
rterial blood flow regulation. Coronary -ARs cause vasocon-
triction, whereas -ARs cause vasodilation. The 1-ARs
onstrict primarily epicardial coronary arteries and large arte-
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ccepted May 19, 2009.ioles, whereas 2-ARs act mostly on the coronary microcir-
ulation (1,2). Stimulation of 1-ARs by endogenous cat-
cholamines produces little constriction of normal coronary
rteries (2–4), but causes pronounced vasoconstriction in
oronary arteries with atherosclerotic endothelium (1,2,4).
The 1-ARs exist as 3 molecular subtypes, 1A, 1B,
nd 1D. All 3 subtypes are activated by norepinephrine
NE) and epinephrine but differ in amino acid sequence,
issue expression, and signaling (5). In the mouse heart,
See page 1146
ardiac myocytes express the 1A and 1B subtypes,
hereas the 1D subtype is functional in coronary arteries
6–8). However, very few data exist on 1-AR subtypes in
he human heart. A single small study of post-mortem tissue
dentified the 1A as the predominant 1-subtype in
picardial coronaries (9). The 1A is also thought to be the
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1D-AR in Human Coronaries September 22, 2009:1137–45predominant 1-AR subtype in
the human myocardium, on the
basis of messenger ribonucleic acid
(mRNA) assay (10). Taken to-
gether, these previous results sug-
gest that 1-AR subtype expres-
sion is different in the human heart
than the mouse heart.
The distribution of cardiac 1-
AR subtypes has significant phys-
iological impact in the mouse,
where the myocardial 1A and
1B mediate adaptive and bene-
ficial effects, including positive
inotropy, physiological hypertro-
phy, and protection from myocyte
death (6,11–13). The coronary
1D mediates vasoconstriction
(7,8). In humans, nonselective
blockade of all 1-subtypes can
be associated with heart failure
(14,15). These results and others
raise the possibility that the hu-
man heart 1A and 1B sub-
types should not be blocked and
might even be targets for selec-
tive agonists to treat myocardial
isease (12,16). Thus, it could be significant clinically if
uman coronary arteries express predominantly the 1D sub-
ype, as in the mouse (7,8), rather than the 1A subtype, as
eported previously (9).
In this study, we re-examined the 1-AR subtypes in
uman epicardial coronary arteries, and measured -ARs
or comparison. Our results show that the 1D is the
redominant and functional coronary 1-AR subtype,
hereas the 1A and 1B are expressed at very low levels.
e contrast this finding with the minimal expression of the
1D in human ventricular myocardium. We also find that
1-AR levels in coronary arteries are approximately one-
hird the level of -ARs, most of which are the 2 subtype.
ethods
atients. With the approval of the University of California,
an Francisco (UCSF) Committee for Human Research
nd with full informed consent, we obtained heart tissue
rom transplant recipients or unused donors provided by the
alifornia Transplant Donors Network (CTDN).
issue collection. The heart was explanted after cold
ardioplegia, under anesthesia and analgesia with fentanyl,
idazolam, rocuronium, and isoflurane at UCSF, and with
aried agents at the CTDN hospitals. The explanted heart
as placed immediately in ice-cold physiologic solution,
picardial coronary arteries were dissected, cleaned rapidly
Abbreviations
and Acronyms
AR  adrenergic receptor
CAD  coronary artery
disease
CTDN  California
Transplant Donors Network
CYP  cyanopindolol
EF  ejection fraction
ERK  extracellular signal-
regulated kinase
LV  left
ventricle/ventricular
MLC  myosin light chain
mRNA  messenger
ribonucleic acid
NE  norepinephrine
qRT-PCR  quantitative
real-time reverse
transcription polymerase
chain reaction
RNA  ribonucleic acid
SMC  smooth muscle cell
UCSF  University of
California, San Franciscof fat, flash frozen in liquid nitrogen, and stored at 80°C. tibonucleic acid (RNA) preparation. Coronaries were
ulverized in a liquid nitrogen-cooled mortar and homoge-
ized (Polytron) in TRIzol reagent (Invitrogen, Gibco BRL,
aithersburg, Maryland). Myocardium was homogenized di-
ectly in TRIzol. The RNA was extracted with chloroform and
sopropanol, purified on Qiagen Mini-Prep columns, and
reated with DNase (Turbo DNAfree, Ambion, Austin,
exas). We found no significant RNA degradation (Agilent
100 BioAnalyzer, Palo Alto, California).
uantitative real-time reverse transcription (RT) poly-
erase chain reaction. The RT reactions used 1 g RNA,
uperScript III Reverse Transcriptase (Invitrogen), random
examers (Invitrogen), and oligo-dT (Roche, Nutley, New
ersey). Quantitative real-time RT polymerase chain reac-
ion (qRT-PCR) was done in triplicate in an ABI PRISM
900HT Sequence Detection System with 5% of the RT
roduct, primers at 125 nmol/l, and SYBR Green Master
Roche) with ROX reference dye. Data were analyzed with
DS software version 2.3 (Applied Biosystems, Foster City,
alifornia).
Relative quantitation of PCR products used the CT
ethod, where arbitrary units were 2CT 1,000, CT
ycles to threshold, and CT (mean target gene CT)
mean CT of 2 reference genes, -actin, and TATA-
inding protein, for improved accuracy).
adioligand binding. Multiple protocols for membrane
reparation from single arteries did not yield sufficient
rotein for reliable binding. Therefore, 15 epicardial coro-
aries totaling 10.2 g wet weight were pooled from 11
atients, pulverized in a liquid nitrogen-cooled mortar,
omogenized in lysis buffer (5 mmol/l Tris-hydrochloride, 5
mol/l ethylenediaminetetraacetic acid, 250 mmol/l su-
rose pH 7.4 plus phenylmethylsulfonyl fluoride), and
entrifuged at 1,000 g for 15 min. The supernatant was
aved, and the pellet containing insoluble material was
ashed in lysis buffer and recentrifuged. The combined
upernatants were centrifuged at 100,000 g for 1 h, and the
esulting pellet was homogenized in lysis buffer and centri-
uged at 100,000 g for 1 h. The resulting final membrane
ellet, containing both plasma and intracellular membranes,
as resuspended (50 mmol/l Tris pH 7.4, 1 mmol/l ethyl-
nediaminetetraacetic acid) and used for 1- and -AR
inding.
The 1-AR saturation binding used 200 g membrane
rotein in 1 ml/tube with 3H-prazosin (0.04 to 1.2 nmol/l,
erkinElmer, Waltham, Massachusetts); phentolamine (10
mol/l, Sigma #P7561) defined nonspecific binding. The
-AR binding used 50 g membrane protein/tube with
25I-cyanopindolol (CYP) (0.04 to 1.0 nmol/l, NEN Life
ciences, PerkinElmer); L-propranolol (1 mol/l, Sigma
P8688) defined nonspecific binding (17). The 1-AR
ubtype proteins were assayed with competition for 3H-
razosin binding (0.5 nmol/l) by BMY-7378 (0.05 nmol/l
o 500 mol/l, Sigma #B134), an 1D-selective antagonist
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September 22, 2009:1137–45 1D-AR in Human Coronaries18). All incubations were 60 min at 30°C. Binding data
ere analyzed by Prism 4.0b (GraphPad Software, Inc., San
iego, California).
oronary artery smooth muscle cell culture and immuno-
lots. Human coronary arteries were digested 20 min in
anks buffer with collagenase Type II (1 mg/ml, Worthing-
on, Lakewood, New Jersey) and elastase (0.5 mg/ml, Worth-
ngton), and intima and adventitia were removed mechanically.
ings of media (approximately 2 mm) were cut free hand and
ultured. Other rings were minced and digested for 2 h in
ollagenase and elastase; enzymes were inhibited with serum;
nd smooth muscle cells (SMCs) grew out of the minces (19).
lonetics normal human coronary artery SMCs were from
onza (#CC2583, Walkersville, Maryland). All cells were
ultured in Dulbecco’s modified Eagle’s medium with 10%
etal bovine serum for 8 to 48 h (rings) or 3 to 11 passages
cells). For experiments, cultures were incubated in Dulbecco’s
odified Eagle’s medium without serum with 5 mg/ml bovine
atient CharacteristicsTable 1 Patient Characteristics
Patient # Age (yrs) Sex M
Without CAD (n  17)
062606 19 M CPVT
070307 22 M AS, H
062107 (b) 26 M AF, R
D-062607 26 F None
112806 (b) 29 F AF, C
D-100406 31 M None
092106 38 F CoH
D-101606 42 M DM,
100906 44 M HF, V
112206 (b) 44 M CKD
112306 (b) 45 F CKD
032007 (b) 45 F HF
060508 (c) 46 M HF, C
032407 (b) 52 F AF, C
050207 55 M CKD
070407 56 M AF, C
080607 70 F HF, C
With CAD (n  8)
D-022807 (b) 50 M CAD
D-053107 (b) 51 M CAD
D-011607 (b) 57 F CAD
081607 (b) 58 M CAD
113006 59 M CAD
021207 59 M AF, C
032507 61 M AS, C
062007 (b) 66 M CAD
Mean  SE % M
All patients 46 3 68
Without CAD 41 3 59
With CAD 58 2* 88
p  0.005; †p  0.05 with versus without CAD. Tissue was from heart transplant recipients (n 
ulture. Clinical data were from University of California, San Francisco computerized medical reco
ACEI  angiotensin-converting enzyme inhibitor; AF  atrial fibrillation/flutter; Amio  amioda
oronary artery disease; CCB  calcium-channel blocker; CKD  chronic kidney disease; CoHD 
olymorphic ventricular tachycardia; D  diuretic; DA  dopamine; Db  dobutamine; Dig  d
ypertension; Hyd  hydralazine; Ins  insulin; Lev  levothyroxine; MI  myocardial infarction; Mil  m
HD  rheumatic heart disease; Sar  sarcoidosis; Sil  sildenafil; VAD  ventricular assist device; Vaserum albumin (Sigma #A7030) for at least 12 h (rings) or 48 h
cells), pretreated without or with 1-antagonists (10 nmol/l
MY-7378; 1 mol/l prazosin, Sigma #P7791) for 90 min
rings) or 15 min (cells) and treated with 1-agonists (1-200
mol/l L-NE, Sigma #N5785; 10 nmol/l A61603, Tocris
1052, Ellisville, Missouri), in the presence of the -AR
ntagonist L-propranolol (1 mol/l). After 30 min (rings) or
5 min (cells), homogenates were made in radioimmunopre-
ipitation assay buffer with protease and phosphatase inhibi-
ors. Ring homogenates were centrifuged at 12,000 rpm for 20
in at 4°C. The supernatant (rings) or total lysates (cells) were
sed (10 to 20 g protein/lane) for immunoblotting with
ntibodies from Cell Signaling for total– extracellular
ignal-regulated kinase (ERK) 1/2 (rabbit pAb #9102) and
hospho-ERK1/2 (rabbit mAb Thr202/Tyr204 #4370) and
ntibodies for phospho-S19/20-myosin light chain 2
MLC), including Sigma #M6068, Cell Signaling #3671,
nd abcam #ab2480.
l History EF (%) Medications
47 Amio, BB, CCB,
18 ACEI, Amio, BB, D, Hyd, Nit
20 BB, D, Hyd, Mil
N/A None
VT 20 ACEI, BB, D, Db, Epi, Mil
65 None
30 ACEI, Amio, BB, D, Lev
55 ACEI, D, PE, Vaso
18 ACEI, Amio, D, Db, Mil
23 ACEI, Amio, BB, D, Lev, Mil, Sil
ar, VTE 30 BB, D, Db, Dig, Hyd, Nit
30 ACEI, Amio, BB, D, Hyd, Nip
26 ARB, BB, D, Dig, Mil
F, HTN 18 D, Db, Dig, Hyd, Nit
12 ACEI, Amio, BB, Hyd, Mil
F, HTN 35 Amio, BB, D, Hyd, Mil, Nit
D, COPD 9 BB, D, Db, Hyd, Nit
70 DA, PE
PSA 59 DA, PE
TN 60 None
DM, HF, HTN 25 Ins, VAD
DM, HF, HTN 41 ARB, BB, D, Ins, Nit
KD, HF, MI 20 Amio, Db, Dig, Nip, Mil
KD, DM 68 ARB, BB, D, Ins, Nit
20 BB, VAD
Mean  SE
34 4
29 4
45 8†
unused donor hearts (D-) (n  6). (b) indicates tissue used in binding assay; (c) indicates used for
he California Transplant Donors Network chart.
RB  angiotensin receptor blocker; AS  aortic stenosis; BB  -blocker; CA  cancer; CAD 
nital heart disease; COPD  chronic obstructive pulmonary disease; CPVT  catecholaminergic
DM  diabetes mellitus; EF  ejection fraction; Epi  epinephrine; HF  heart failure; HTN edica
F
HD
oHD,
D, HF
HTN
TE
, HF
, HF, S
OPD
KD, H
, HF
KD, H
A, CK
, PSA
, HTN,
, DM, H
, CKD,
, CKD,
AD, C
AD, C
19) or
rds or t
rone; A
conge
igoxin;
ilrinone; Nip  nitroprusside; Nit  nitrates; PE  phenylephrine; PSA  polysubstance abuse;
o  vasopressin; VT  ventricular tachycardia; VTE  venous thromboembolic disease.
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1D-AR in Human Coronaries September 22, 2009:1137–45ata analysis. Results are mean  SEM. Significant differ-
nces (p  0.05) were tested with analysis of variance and
ukey’s multiple comparison for more than 2 groups and
tudent unpaired t test for 2 groups. The F test was used to
ompare goodness-of-fit for competition binding analysis
GraphPad Prism version 4.0). Multivariate linear regression
Stata version 9, Stata Corp., College Station, Texas) was used
o determine whether clinical variables were independently
ssociated with 1- and -AR density. Multivariate model
ssumptions were checked for all regression analyses.
esults
atients. To test 1-AR subtype expression in human
oronary arteries, we collected hearts from 19 transplant
ecipients and 6 unused donors. Average age was 46 years
range 19 to 70 years), and 68% were male (Table 1).
oronary artery disease (CAD) was present in 32%, who
ere older (p  0.005) and had higher ejection fractions
EFs) (p  0.05) (Table 1).
1-AR subtype mRNA levels. To quantify 1-subtype
RNAs, we validated a qRT-PCR approach, with primers
hat span the single intron in each 1-AR subtype gene.
rimer pairs were designed with Primer3 (version 0.4.0) and
LAST (Basic Local Alignment Search Tool) and chosen
or comparable reaction efficiencies (20). Specificity of the
1-subtype primers was confirmed with: 1) PCR with human
1-AR complementary deoxyribonucleic acid; 2) a dissoci-
tion step in all PCR reactions; and 3) sequencing of the
CR products. Amplification of genomic deoxyribonucleic
cid was excluded by: 1) use of intron-spanning primers; 2)
Nase treatment of RNA; and 3) end point PCR reactions
ith no-RT templates as negative controls.
In human epicardial coronary arteries, the 1D was 85% of
otal 1-mRNA (Fig. 1A). The 1B (11%) and the 1A (4%)
ere markedly less abundant than the 1D (p  0.001 for
ach). In LV myocardium, by contrast, the 1D was only 21%
f the total 1-mRNA, and the 1A (63%) was the most
bundant (Fig. 1B). The absolute level of 1D mRNA in
oronary arteries was almost twice that in LV (p  0.01),
hereas the absolute level of the 1A was 30-fold higher in
V than in coronary arteries. As a control, there was no
ifference between coronary arteries and myocardium in the
RT-PCR cycles-to-threshold for the reference genes,
-actin, and TATA-binding protein. Levels of 1-subtype
RNAs were the same in 4 right and 4 left anterior descend-
ng coronaries (data not shown). There were no differences in
1-subtype mRNA levels in coronaries collected at UCSF
ersus the CTDN hospitals, suggesting no important effects
ue to anesthetic and analgesic agents (data not shown).
In summary, the 1D is 85% of total 1-AR subtype
RNA in human epicardial coronary arteries but is signif-
cantly less abundant in human LV myocardium.
1-AR subtype protein levels. To test 1-AR subtype
rotein levels we used radioligand binding with 3H-
razosin. We could not use immunohistochemistry or mmunoblot, because none of the 10 1-AR antibodies that
e tested is specific for 1-ARs (21).
We used pooled membranes from 11 patients for binding.
atient characteristics were similar in these 11 patients and
he entire patient population (Table 1), and the 1-subtype
RNA levels in the pooled samples were similar to the
evels of the entire group (data not shown). Saturation
inding identified 8.7 fmol/mg protein of total 1-ARs in
oronary artery membranes, with a Kd 0.03 nmol/l, and
pecific binding 70% of total at the 3H-prazosin Kd (Fig. 2).
he level of 1-AR binding in coronaries was roughly twice
hat in LV myocardium (20).
To test whether the 1D subtype protein was also predom-
nant in coronaries, as with mRNA, we did competition
inding with the 1D-selective antagonist BMY-7378. The
MY-7378 competition yielded a 2-site binding curve (p 
.002 vs. 1-site model), with 75% high-affinity sites (Kd 13
mol/l) and 25% low-affinity (2.6 mol/l) (Fig. 3A, Table 2).
n ventricular myocardium, BMY competition gave a 1-site
urve with low BMY-7378 affinity, indicating minimal or no
Figure 1 1-AR Subtype mRNA Levels
in Coronary Arteries and Left Ventricle
Quantitative real-time reverse transcription polymerase chain reaction of 1-adren-
ergic receptor (AR) subtypes in (A) human coronary arteries and (B) left ventricle
free wall. mRNA  messenger ribonucleic acid; TBP  TATA-binding protein.1D binding (Fig. 3B).
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September 22, 2009:1137–45 1D-AR in Human CoronariesIn summary, the 1D is 75% of total 1-AR subtype
rotein in human epicardial coronary arteries but is much
ess abundant in myocardium. The coronary levels of 1D
RNA and protein agree very well (Table 2).
1-AR signaling in coronary SMCs. To test whether the
1D was functional in human coronary SMCs, we used
mmunoblot to quantify phosphorylation (activation) of
RK, which is a target for the 1D in rat aortic SMCs (22)
nd is involved in activation of MLC kinase in smooth
uscle (23). We used SMCs from Lonza, coronary media
ings, and primary isolates from the coronary medial SMC
ayer (Fig. 4). A qRT-PCR for -smooth muscle actin and
mooth muscle myosin heavy chain confirmed SMC iden-
ity, and 1D mRNA was the predominant 1-subtype,
ith less 1B and no 1A (data not shown). Low concen-
rations of NE (mean 27 nmol/l), in the presence of
ropranolol to block -ARs, induced a 1.8-fold increase in
hospho-ERK, and activation was abrogated to an equal
xtent by a low concentration of BMY-7378 (10 nmol/l),
he 1D-selective antagonist, and prazosin, the nonselective
Figure 2 1- and -AR Protein Levels by Saturation Binding
Saturation radioligand binding was done in membranes pooled from 15 epicar-
dial coronary arteries of 11 patients. (A) Binding with 3H-prazosin for total
1-adrenergic receptors (ARs); (B) binding with 125I-CYP for total -ARs. CYP 
cyanopindol; DPM  disintegrations/minute.1-antagonist (Fig. 4). The 1A-selective agonist, A6160310 to 100 nmol/l), did not activate ERK (data not shown).
hospho-MLC was barely detectable with 3 different anti-
odies and was not useful as a read-out (data not shown).
We conclude that the 1D is functional in human
picardial coronary SMCs, whereas there is no evidence for
he 1A.
-AR mRNA and protein levels. We measured -AR
RNAs and protein in the same coronary arteries, to
ompare with 1-ARs. By qRT-PCR (20) the 2 was the
redominant -subtype mRNA (99% of total -AR
RNA) (Table 2). Total 1-AR mRNA was 37% of total
-AR mRNA (p  0.0001) (Table 2).
The -AR proteins were quantified by saturation bind-
ng, because the available -AR antibodies are not specific
n our hands (12). Saturation binding with 125I-CYP, a
onselective -AR antagonist, identified 25.2 fmol/mg
rotein of total -ARs in coronary artery membranes, with
Kd 0.16 nmol/l and specific binding 41% of total at the
25I-CYP Kd (Fig. 2B). Given the preponderance of 2-
RNA in coronary tissue, -AR competition binding was
ot done. Total 1-AR binding was 35% of total -AR
inding, in excellent agreement with the mRNA values
Table 2).
  Coronary Arteries
  Ventricular Myocardium 
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Figure 3 1-AR Subtype Protein Levels
by Competition Binding
Competition for 3H-prazosin binding by the 1D-selective antagonist BMY-7378
yielded (A) a 2-site binding curve with predominantly high-affinity sites in coro-
nary artery membranes; (B) a 1-site low affinity curve in ventricular myocardium
from 3 patients. AR  adrenergic receptor.
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1D-AR in Human Coronaries September 22, 2009:1137–45In summary, the 2 was the predominant -AR subtype
n epicardial coronary arteries, and 1-AR mRNA and
inding were only one-third of -ARs.
mpact of clinical variables on coronary 1- and -AR
RNA levels. The qRT-PCR results were analyzed to
etermine whether clinical variables affected the expression of
R subtypes in human coronaries. Human noncoronary arte-
ial and prostate 1-ARs are said to increase with age (9,24),
nd 1-mediated vasoconstriction is more prominent in CAD
1–4). However, we found that age, EF, -agonist exposure,
AD (Fig. 5), and sex (data not shown) had no effect on
oronary artery 1-subtype mRNA levels. Interestingly, 1D
nd total 1-mRNA levels were 35% lower in coronary arteries
f patients using -blockers (p  0.04). This association
ersisted after adjusting for age, sex, CAD, and EF (p 0.03)
Fig. 5B). Among -blockers, 1D mRNA levels appeared
imilar among patients taking metoprolol (1 patient), nadolol
1 patient), or carvedilol (8 patients) (Fig. 5B).
The levels of coronary -AR mRNAs, which were almost
ntirely 2, did not vary with age, EF, -blocker or
-agonist use, or sex (data not shown).
In summary, age, sex, CAD, EF, and -agonists had no
ignificant effect on 1- or -subtype mRNA levels in
oronary arteries. Beta-blocker use was associated with a
ignificant decrease in 1D and total 1-mRNA levels.
iscussion
his study reports that the 1D subtype is the predominant
1-AR mRNAs and Proteins in Human Epicardial Coronary ArteriesTable 2 1-AR mRNAs and Proteins in Human Epicardial Coron
mRNA
AU %
Coronary artery
1-AR
1A 2 1 4
1B 5 1 11
1D 39 4* 85
Total 1 46 4† 100
-AR
1 1 0 1
2 124 12 99
Total  125 12 100
Total 1- and -AR 171
Total 1/total  37
TBP and -actin mRNAs
LV free wall
1-AR
1A 66 9 63
1B 17 3 16
1D 22 5 21
Total 1 105 11 100
TBP and -actin mRNAs
he 1- and -adrenergic receptor (AR) subtype messenger ribonucleic acid levels (mRNAs) were q
rbitrary units (AU) (mean  SE) normalized to TATA-binding protein (TBP) and -actin mRNAs; n 
-AR binding were quantified by saturation analysis in membranes pooled from 15 arteries of 11
p  0.01 1D in coronary versus in LV free wall; †p  0.0001 total 1 mRNA versus total -AR1-AR in human epicardial coronary arteries, comprising approximately 80% of total 1-AR mRNA and protein.
hese data also reveal that coronary 1-AR levels are only
ne-third of -ARs. This is the most extensive character-
zation of 1-AR subtypes in coronary tissue in any species.
Our results disagree with those of a previous investigation
hat identified the 1A as the predominant 1-subtype in
uman coronary arteries (9). In our study, the 1A in the
oronaries was only 4% of total 1-mRNA in coronaries
nd was absent in isolated SMCs, and the combined 1A
nd 1B were only 25% of total 1-binding. The discrep-
ncy might be explained by the prior study’s small sample
ize (5 arteries from an unspecified number of patients), the
se of post-mortem tissue, or a qualitative RNA assay
RNase protection) (9).
Of particular importance is our finding that the 1-AR
ubtype profiles in the human coronary arteries and ventric-
lar myocardium were quite different. Previous limited
vidence suggests that 1A subtype mRNA is predominant
n both coronary arteries and myocardium (9,10). In con-
rast, we found that the 1D was predominant in the
oronary arteries but was much less abundant in the myo-
ardium, where 1A mRNA was predominant. In the
ouse heart, myocardium has the 1A and 1B subtypes
6), whereas the 1D subtype is functional in coronary
rteries (7,8). Thus, rodents and humans might have similar
1-AR subtype expression in coronary arteries and myocar-
ium (7,8,17,20,25–27) (Table 3), contrary to prior claims
9), and studies done in mouse models might therefore be
rteries
Binding
Cycles to
Thresholdfmol/mg %
2.2 25
6.5 75
8.7 100
25.2 100
34
35
20.8 0.6
22.1 0.4
d by quantitative real-time reverse transcription polymerase chain reaction. The mRNA values are
1 in coronaries; n  20,  in coronaries; n  18, 1 in left ventricular (LV) free wall. The 1- and
s, indicated by (b) in Table 1, and % 1D subtype was estimated by competition with BMY-7378.
.ary A
uantifie
22, pplicable to human cardiac 1-AR biology.
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September 22, 2009:1137–45 1D-AR in Human CoronariesTechnical aspects of this study warrant emphasis. We
tudied coronaries from a large number of patients of both
exes without and with CAD or heart failure and assessed
he effects of these variables on 1-AR expression. We took
xtensive measures to validate our qRT-PCR approach. We
uantified 1-subtype proteins by competition binding,
ecause binding is for now the only accurate method to
easure 1-AR proteins (21).
We also measured -AR subtypes in the coronaries and
ound that 1-AR levels were only one-third of -ARs.
Figure 4 1-AR–Induced ERK Activation
in Human Coronary Artery SMCs
Cultured human epicardial coronary smooth muscle cells (SMCs) and coronary
media rings were treated for 15 to 30 min with low concentrations of norepi-
nephrine (NE) (1 to 200 nmol/l, mean 27 nmol/l), and the nonselective -ad-
renergic receptor (AR) antagonist propranolol (1 mol/l), in the absence or
presence of the 1D-selective antagonist BMY-7378 (10 nmol/l) or the nonse-
lective 1-antagonist prazosin (1 mol/l). (A) Western blot showing extracellu-
lar signal-regulated kinase (ERK) activation in duplicate dishes from a Lonza
(Walkersville, Maryland) SMC culture; (B) summary data for 8 Lonza SMC prep-
arations from 2 patients, a ring preparation from 1 patient, and 2 primary SMC
cultures from 1 patient.
ardiac 1-AR Subtypes in Human, Mouse, and RatTable 3 Cardiac 1-AR Subtypes in Human, Mouse, and Rat
Human
Coronary 1-AR subtype 1D*
Evidence mRNA, binding, pharmacology
Myocardial 1-AR subtype 1A and 1B‡
mRNA A (63%)  B (16%), D (21%)
Binding B (60%)  A (40%)  D (0%)
eferences: *present study; †Turnbull et al. (7), Chalothorn et al. (8); ‡Jensen et al. (20); §Myagm
t al. (26).
KO  knockout; other abbreviations as in Tables 1 and 2.owever, these lower 1-AR levels do not negate the
hysiological significance of the 1D. The contractile re-
ponse to NE in isolated human epicardial coronary arteries
s constriction at low concentrations (nmol/l) and relaxation
t high concentrations (mol/l) (28). The 1D has the
ighest NE affinity of any subtype (29), and thus constric-
ion at low NE concentrations is consistent with an 1D-
esponse. The larger population of coronary -ARs could
ediate relaxation with mol/l NE.
Indeed, our experiments in epicardial coronary SMCs
evealed that the 1D mediated activation of ERK by low
oncentrations of NE (Fig. 4). ERK is activated by the 1D
n rat aortic SMCs (22), and ERK phosphorylation facili-
ates activation of MLC kinase in smooth muscle, thus
ontributing to the adrenergic contractile response (23).
hese findings suggest that the 1D is both abundant and
unctional in human epicardial coronary arteries.
We analyzed coronary 1- and -AR subtype mRNA
evels by age, CAD, EF, -blockers, and -agonists (Fig. 5)
nd sex (data not shown). The only association we found
as a decrease in the 1D and total 1-ARs in patients
reated with -blockers, possibly implying that 1D expres-
ion in coronary vascular cells is increased by -stimulation.
n fact, in human monocytes, 2-stimulation induces 1D
RNA and protein (30).
Coronary 1-subtype mRNA levels did not differ in
atients with CAD versus without CAD. This was note-
orthy, because 1-ARs cause pronounced vasoconstriction
n atherosclerotic coronary arteries but have little effect in
ormal coronaries (1–4). Thus, increased 1D levels in
oronary vascular SMCs might not explain augmented
1-vasoconstriction in CAD. Instead, a small population of
ndothelial cell 1-ARs mediating endothelium-dependent
asodilation (31) could be lost in CAD.
linical implications. Important clinical implications de-
ive from the predominance of the 1D subtype in human
oronary arteries. Cell and animal models show that the
ardiac myocyte 1A and 1B subtypes have significant
daptive and protective roles (6,11–13,16). Clinical trials
lso suggest 1-mediated cardioprotection, because nonse-
ective antagonism of all 1-subtypes was associated with a
-fold excess of heart failure in the doxazosin arm of the
LLHAT (Antihypertensive and Lipid-Lowering treat-
ent to prevent Heart Attack Trial), and a trend towards
Mouse Rat
Unknown
onstriction, KO studies
nd 1B§ 1A and 1B
%)  B (49%)  D (4%)* A (65%)  B (27%)  D (8%)
%)  A (30%)  D (0%) B (74-80%)  A (20%–26%)  D (0%)
l., unpublished data, 2009, and Simpson (27); Rokosh et al. (17), Stewart et al. (25), and Michel1D†
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1D-AR in Human Coronaries September 22, 2009:1137–45ncreased mortality in the prazosin arm of the V-HeFT
Vasodilator-Heart Failure Trial) (14,15).
Despite the ALLHAT trial results, 13.4 million prescrip-
ions were dispensed in 2002 for mostly nonselective
-blockers (32), primarily to treat symptoms from prostate
ypertrophy. However, the 1D-selective antagonist, naf-
opidil, is effective in relieving prostate symptoms (33). In
ight of our results, it seems possible that more selective
ntagonism of the 1D subtype might relax both coronary
nd prostate smooth muscle, without blocking beneficial
Figure 5 1-Subtype mRNA Levels by Clinical Variables
Quantitative real-time reverse transcription polymerase chain reaction for 1-subty
to (A) coronary artery disease (CAD); (B) -blocker use, all carvedilol, except meto
tion fraction. The p values are for multivariate analysis.ignaling mediated by the myocardial 1A and 1B sub- hypes. Furthermore, the adaptive and protective roles of the
yocardial 1A and 1B raise the intriguing possibility of
ctivating one or both of these subtypes selectively to treat
yocardial disease (16). The low levels of the 1A and 1B
n human coronary arteries would make 1A- or 1B-
gonist–induced coronary vasoconstriction unlikely.
onclusions
e present here the most extensive characterization of
ssenger ribonucleic acid (mRNA) levels and all 1 mRNA are displayed according
(circles) and nadolol (squares); (C) -agonist exposure; (D) age; and (E) ejec-pe me
prololuman coronary ARs to date. We show that the 1D is the
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September 22, 2009:1137–45 1D-AR in Human Coronariesredominant 1-AR subtype in human epicardial coronary
rteries—not the 1A as reported previously (9)—and that
he 1D is low in myocardium. The 1A and 1B are
resent in coronaries at very low levels, and total 1-AR
evels are one-third the level of -ARs, most of which are
he 2 subtype. The tissue distribution of 1-subtypes in
he human heart is similar to the rodent heart (Table 3).
hese results are clinically relevant to the widespread use of
1-antagonists and to the potential development of 1A-
nd/or 1B-AR–selective agonists.
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